Rituximab for myasthenia gravis developing after bone marrow transplant.
Zaja
F
F
Department of Clinical and Morphological Research, University Hospital and School of Medicine, Udine, Italy. Ematologia@drmm.uniud.it
Russo
D
D
Fuga
G
G
Perella
G
G
Baccarani
M
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab